# TITAN-RCC (NCT02917772)

> Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02917772
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: AIO-Studien-gGmbH
- Conditions: Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma
- Interventions: Nivolumab/Ipilimumab
- Enrollment: 200
- Primary outcome: Objective Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 17
- Podcasts: 3
- YouTube: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=titan-rcc-nct02917772

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02917772", "email": "<work email>"}; the inbox owner confirms by the emailed link.